Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2012

View Archived Issues

Shire provides pipeline overview for third quarter of 2012

Lupin presents novel nicotinic acetylcholine receptor modulators

Neuraltus Pharmaceuticals reports phase II results for NP-001 in ALS

Ocular Therapeutix reports results from phase II OTX-TP2 study

Ultragenyx completes enrollment in phase II UX-001 study

Kyowa Hakko Kirin reviews developments of third quarter 2012

Adcetris granted conditional approval in Europe for two indications

Summit initiates phase I study of SMT-19969 for C. difficile infection

RaQualia Pharma and Ajinomoto Pharmaceuticals establish collaboration

Results from phase III study of masitinib plus Gemzar for pancreatic cancer presented

Shionogi and Janssen enter collaboration for Alzheimer's disease

Two Cytori cell therapy studies approved by Japanese authorities

Key milestone reached for TSRL with the FDA for TSR-026

Roche presents new SYK kinase inhibitors

Korean scientists patent novel DPP IV inhibitors

Incyte discloses new PI3Kdelta inhibitors

New nACh alpha7 receptor modulators patented by Lundbeck

Novel cannabinoid CB1 receptor antagonists synthesized by Korean group

Results presented for randomized phase II study of tivantinib

Bristol-Myers Squibb divulges new prodrugs of LXR modulators

Results presented from phase II trial of dovitinib in GIST

Strategic collaboration reached for Firdapse in North America

Phenex's PX-102 proves safe and well tolerated in phase I study

Novo Nordisk completes phase I trial of oral GLP-1 analogue

Avastin obtains E.U. approval for recurrent, platinum-sensitive ovarian cancer

Karo Bio presents agent with potential for preventing multiple sclerosis progression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...